Orchestra BioMed Holdings (OBIO) Cash & Equivalents (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has 7 years of Cash & Equivalents data on file, last reported at $28.4 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 54.61% year-over-year to $28.4 million in Q1 2026; TTM through Mar 2026 was $28.4 million, a 54.61% increase from a year earlier, with the FY2025 full-year figure at $84.6 million, up 48.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $28.4 million, down from $84.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for OBIO reached as high as $114.6 million in Q2 2023 and fell as low as $735217.0 in Q3 2022.
• Historically, Cash & Equivalents has averaged $34.5 million across 5 years, with a median of $23.3 million in 2024.
• Across the five-year window, Cash & Equivalents surged 8666.88% in 2023 and plunged 65.24% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $19.8 million in 2022, then surged by 54.46% to $30.6 million in 2023, then soared by 85.87% to $56.8 million in 2024, then jumped by 48.97% to $84.6 million in 2025, then slumped by 66.47% to $28.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $28.4 million in Q1 2026, $84.6 million in Q4 2025, and $42.0 million in Q3 2025.